MRKR Nasdaq Pharmaceutical Preparations Financials FY2016βFY2025
Marker Therapeutics, Inc. had $3.5M of revenue in fiscal 2025, down 46.2% on the year before. Over five years, revenue changed +48.0% a year on average.
Last close Β· Oct 23, 2026
$0.96
10.3%Hi! I read Marker Therapeutics, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β46.2%
No. Sales fell 46.2% last year.
Does it make a profit?
β343.0%
No. It lost money last year.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
KIRA Β· Marker Therapeutics, Inc. had $3.5M of revenue in fiscal 2025, down 46.2% on the year before. Over five years, revenue changed +48.0% a year on average. Its operating margin was β363.4%, down 194.8Β pts: of every 100 in sales, about β363 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Marker Therapeutics, Inc. lost $12.2M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Marker Therapeutics, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $42.4M | $11.8M | $15.1M | $19.2M | $16.1M |
| Current ratio | 3.6x | 2.1x | 5.6x | 6.4x | 8.4x |
| Quick ratio | 3.6x | 2.1x | 5.6x | 6.4x | 8.4x |
| Total assets | $68.1M | $34.4M | $17.1M | $22.0M | $19.1M |
| Total liabilities | $24.1M | $14.8M | $3.1M | $3.5M | $2.3M |
| Shareholders' equity | $44.0M | $19.6M | $14.1M | $18.6M | $16.8M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Marker Therapeutics, Inc. passes 2 of 7 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | β / 6 | 2 / 7 | 4 / 7 | 2 / 7 | 3 / 7 | 2 / 7 | 3 / 7 | 2 / 7 | 2 / 7 |
| Accruals ratio | 51.2% | β38.8% | β396.5% | β5.8% | β18.9% | β25.7% | β5.8% | 31.8% | 0.9% | β0.7% |
| Altman Z'' | β58.35 | β106.80 | β3.61 | 0.22 | β25.55 | β17.84 | β41.33 | β78.58 | β58.41 | β69.50 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | β | $0.2M | $0.2M | $0.2M | $0.5M | $0.0M | $3.5M | $3.3M | $6.6M | $3.5M |
| Research and development | $3.8M | $5.3M | $8.0M | $12.8M | $18.9M | $27.8M | $12.0M | $10.4M | $13.5M | $11.8M |
| Operating income | β$8.5M | β$11.5M | β$148M | β$22.5M | β$28.9M | β$39.5M | β$19.8M | β$14.6M | β$11.1M | β$12.9M |
| Pretax income | β | β | β | β | β | β | β$19.8M | β$14.0M | β$10.7M | β$12.2M |
| Income tax | $0.0M | $0.0M | $0.0M | β | β | β | β | $0.0M | $0.1M | β$0.0M |
| Net income | β$2.5M | β$11.0M | β$148M | β$21.4M | β$28.7M | β$41.9M | β$29.9M | β$8.2M | β$10.7M | β$12.2M |
| Diluted EPS | β$0.72 | β$1.16 | β$7.75 | β$0.47 | β$0.61 | β$5.47 | β$3.58 | β$0.94 | β$1.19 | β$0.79 |
| Diluted shares | 0.01B | 0.01B | 0.02B | 0.05B | 0.05B | 0.01B | 0.01B | 0.01B | 0.01B | 0.02B |
| Cash flow | ||||||||||
| Cash from operations | β$6.5M | β$8.4M | β$14.5M | β$18.3M | β$20.0M | β$27.3M | β$27.0M | β$16.4M | β$10.9M | β$12.0M |
| Capital expenditure | β | $0.0M | $0.1M | $0.4M | β | β | β | β | β | β |
| Free cash flow | β | β$8.4M | β$14.6M | β$18.7M | β | β | β | β | β | β |
| Depreciation and amortization | β | β | $0.0M | $0.1M | $0.5M | $2.1M | $2.8M | β | β | β |
| Stock-based compensation | $1.6M | $2.7M | $16.4M | $5.4M | $5.2M | $6.0M | $3.3M | $0.9M | $0.2M | $0.5M |
| Share buybacks | $0.0M | $0.3M | $0.1M | β | β | β | β | β | β | β |
| Dividends and buybacks | $0.0M | $0.3M | $0.1M | β | β | β | β | β | β | β |
| Balance sheet | ||||||||||
| Cash and short-term investments | $7.9M | $5.1M | $61.7M | $43.9M | $21.4M | $42.4M | $11.8M | $15.1M | $19.2M | $16.1M |
| Current assets | $7.9M | $5.2M | $62.0M | $45.5M | $24.4M | $46.0M | $16.6M | $17.1M | $22.0M | $19.1M |
| Current liabilities | $1.7M | $1.5M | $2.8M | $2.0M | $6.4M | $12.9M | $7.8M | $3.1M | $3.5M | $2.3M |
| Property and equipment, net | β | $0.0M | $0.1M | $0.4M | $10.4M | $12.3M | $12.3M | β | β | β |
| Total assets | $7.9M | $5.2M | $62.1M | $46.4M | $45.6M | $68.1M | $34.4M | $17.1M | $22.0M | $19.1M |
| Total liabilities | $1.7M | $1.5M | $2.8M | $2.3M | $18.3M | $24.1M | $14.8M | $3.1M | $3.5M | $2.3M |
| Preferred stock | $0.0M | β | β | β | β | β | β | β | β | β |
| Shareholders' equity | $6.2M | $3.7M | $59.3M | $44.1M | $27.3M | $44.0M | $19.6M | $14.1M | $18.6M | $16.8M |
| Margins | ||||||||||
| Operating margin | β | β6,269.8% | β71,928.0% | β10,567.0% | β5,777.2% | β | β563.3% | β440.4% | β168.7% | β363.4% |
| EBITDA margin | β | β | β71,928.0% | β10,517.7% | β5,680.0% | β | β483.9% | β | β | β |
| Net margin | β | β5,997.9% | β71,824.2% | β10,050.7% | β5,741.2% | β | β851.9% | β248.8% | β162.8% | β343.0% |
| FCF margin | β | β4,609.2% | β7,100.8% | β8,752.0% | β | β | β | β | β | β |
| Returns | ||||||||||
| Return on capital employed | β137.3% | β313.8% | β249.7% | β50.8% | β73.7% | β71.5% | β74.3% | β103.8% | β59.9% | β76.7% |
| Return on equity | β39.7% | β223.2% | β469.7% | β41.4% | β80.4% | β117.4% | β94.1% | β49.0% | β65.8% | β68.8% |
| Return on assets | β31.0% | β167.6% | β439.5% | β39.5% | β62.4% | β73.6% | β58.4% | β32.0% | β54.8% | β59.2% |
| Return on tangible equity | β39.7% | β300.2% | β249.3% | β48.6% | β105.0% | β95.2% | β152.7% | β58.6% | β57.8% | β72.4% |
| Growth | ||||||||||
| Revenue growth | β | β | 12.5% | 3.5% | 134.5% | β100.0% | β | β5.8% | 99.1% | β46.2% |
| Share count change | β | 27.4% | 102.0% | 138.8% | 3.2% | β83.7% | 9.2% | 5.5% | 1.9% | 70.5% |
| Financial health | ||||||||||
| Current ratio | 4.6x | 3.4x | 22.1x | 22.8x | 3.8x | 3.6x | 2.1x | 5.6x | 6.4x | 8.4x |
| Quick ratio | 4.6x | 3.4x | 22.1x | 22.8x | 3.8x | 3.6x | 2.1x | 5.6x | 6.4x | 8.4x |
| Capital allocation | ||||||||||
| Capex / revenue | β | 0.0% | 71.7% | 175.9% | β | β | β | β | β | β |
| Stock comp / revenue | β | 1,495.5% | 7,937.2% | 2,512.7% | 1,045.7% | β | 94.1% | 25.9% | 3.7% | 15.2% |
| Quality scores | ||||||||||
| Piotroski F-score | β | β | 2.0 | 4.0 | 2.0 | 3.0 | 2.0 | 3.0 | 2.0 | 2.0 |
| Altman Z'' | β58.4 | β106.8 | β3.6 | 0.2 | β25.6 | β17.8 | β41.3 | β78.6 | β58.4 | β69.5 |
| Accruals ratio | 51.2% | β38.8% | β396.5% | β5.8% | β18.9% | β25.7% | β5.8% | 31.8% | 0.9% | β0.7% |
Source: SEC EDGAR XBRL filings (CIK 0001094038). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
